Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carmustine + cisplatin + cyclophosphamide + doxorubicin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen that includes five different anticancer drugs: carmustine (BCNU), cisplatin (cDDP), cyclophosphamide (CPA), doxorubicin (Adriamycin), and fluorouracil (5-FU). The regimen has been studied as a high-dose consolidation therapy following standard-dose adjuvant chemotherapy in high-risk primary breast cancer patients, particularly those with multiple positive lymph nodes. The treatment approach typically involves initial treatment with standard-dose CAF (cyclophosphamide, doxorubicin, and fluorouracil) followed by high-dose CPA/cDDP/BCNU with autologous bone marrow support (ABMS).
02
Targets
TOP2A (DNA topoisomerase II)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on carmustine + cisplatin + cyclophosphamide + doxorubicin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carmustine + cisplatin + cyclophosphamide + doxorubicin + fluorouracil.